https://www.selleckchem.com/products/a2ti-1.html
To study the clinical efficacy of allo-HSCT on FLT3-ITD positive AML patients. The clinical data and curative efficacy of 56 FLT3-ITD AML patients treated with allo-HSCT in our hospital from January 2012 to December 2018 were analyzed and evaluated. Neutrophil implantation was successful for all the patients; The median time of granulocyte hematopoietic reconstruction and megakaryocyte hematopoietic reconstruction was 13 (10-2 d and 15 (9-23) d respectively. The median follow-up time for patients 34.3 (5.6-101.4) months, 41 patients we
Respect!
Kommentar
Delen
